According to a recent LinkedIn post from Xeltis, the company’s team plans to attend the Charing Cross (CX) Symposium in London, described in the post as a leading global vascular and endovascular meeting. The post highlights two podium presentations featuring new 12‑month multicenter EU pivotal trial data for Xeltis’ aXess vascular access conduit, delivered by key opinion leaders in vascular surgery.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post outlines a session on aXess 12‑month results and another on a next‑generation bioabsorbable conduit for bypass, suggesting ongoing clinical validation efforts in dialysis vascular access. Senior Xeltis executives, including the CEO, CMO and clinical leadership, are expected to be on site and host a booth, indicating a coordinated push to engage clinicians and potential partners around the emerging data.
For investors, the planned disclosure of 12‑month pivotal trial outcomes may be an important milestone for assessing aXess’ clinical performance and potential path toward regulatory and commercial inflection points. Positive interpretation of the data by the medical community at CX could strengthen Xeltis’ positioning in the vascular access and dialysis segments, potentially supporting future financing, strategic collaborations or market entry plans.
The emphasis on bioabsorbable conduit technology in the program suggests Xeltis is targeting differentiation versus conventional synthetic grafts, in a market where durability and complication rates materially affect healthcare costs. If the pivotal data ultimately translate into improved outcomes and adoption, Xeltis could capture a share of the vascular access market, though the post does not provide specific efficacy metrics, timelines or regulatory guidance that would allow a detailed financial forecast.